Selected Publications#

Selection of most relevant papers
• Paterka M*, Voss JO*, Werr J*, Reuter E, Franck S, Leuenberger T, Herz J, Radbruch H, Bopp T, Siffrin V§, Zipp F§ (2017) Dendritic cells tip the balance towards induction of regulatory T cells upon priming in experimental autoimmune encephalomyelitis. J Autoimmun 76:108-114 *,§equally contributing
• Paterka M, Siffrin V, Voss JO, Werr J, Hoppmann N, Gollan R, Belikan P, Bruttger J, Birkenstock J, Esplugues E, Yogev N, Flavell RA, Bopp T, Zipp F. (2016) Gatekeeper role of antigen-presenting CD11c+ cells in neuroinflammation. EMBO J 35: 89.
• Ulges A*, Witsch EJ*, Pramanik G, Klein M, Birkner K, Bühler U, Wasser B, Luessi F, Stergiou N, Dietzen S, Brühl TJ, Bohn T, Bündgen G, Kunz H, Waisman A, Schild H, Schmitt E, Zipp F§, Bopp T§ (2016) Protein kinase CK2 governs the molecular decision between encephalitogenic TH17 cell and Treg cell development. Proc Natl Acad Sci USA 113(36): 10145-50. *,§ equally contributing
• Larochelle C, Uphaus T, Prat A, Zipp F (2016) Secondary progression in multiple sclerosis: neuronal exhaustion or distinct pathology? Trends Neurosci 39(5):325-339.
• Walsh JT, Hendrix S, Boato F, Smirnov I, Zheng J, Lukens JR, Gadani S, Hechler D, Gölz G, Rosenberger K, Kammertöns T, Vogt J, Vogelaar C, Siffrin V, Radjavi A, Fernandez-Castaneda A, Gaultier A, Gold R, Kanneganti T-D, Nitsch R, Zipp F§, and Kipnis J§ (2015) MHCII-independently induced T-cells protect injured CNS neurons via IL-4. J Clin Invest; 125: 699 §equally contributing and both corresponding
• Hoppmann N, Graetz C, Paterka M, Poisa-Beiro L, Larochelle C, Hasan M, Lill CM, Zipp F§, and Siffrin V§ (2015) New candidates for CD4 T cell pathogenicity in experimental neuroinflammation and multiple sclerosis. Brain 138(4):902-17. §equally contributing.
• Zipp F, Gold R, Wiendl H (2013) Identification of inflammatory neuronal injury and prevention of neuronal damage in Multiple Sclerosis – hope for novel therapies? JAMA Neurology 70:1569–74.
• Liblau R, Gonzalez-Dunia D, Wiendl H, Zipp F (2013) Neurons as targets for T cells in the nervous system. Trends Neurosci 36:315-324.
• Jolivel V, Luessi F, Masri J, Kraus S, Hubo M, Poisa-Beiro L, Klebow S, Paterka M, Yogev N, Tumani H, Furlan R, Siffrin V, Jonuleit H, Zipp F§, Waisman A§ (2013) Modulation of dendritic cell properties by laquinimod as a mechanism for modulating Multiple Sclerosis. Brain 136: 1048-1066.
• The International Multiple Sclerosis Genetics Consortium (IMSGC), last and corresponding author: Zipp F (2013) MANBA, CXR5, SOX8, RPS6KB1 and ZBTB46 are genetic risk loci for multiple sclerosis. Brain 136:1778-82.
• Methner A, Zipp F (2013) Multiple Sclerosis in 2012: Novel therapeutic options and drug targets in MS. Nat Rev Neurol 9:72-3.
• Roep BO, Buckner J, Sawcer S, Toes R, Zipp F. (2012) The problems and promises of research into human immunology and autoimmune disease. Nat Med 18: 48.
• The International Multiple Sclerosis Genetics Consortium (IMSGC) and the Wellcome Trust Case Control Consortium 2 (WTCCC2) (Leading Center Cambridge; Zipp F as part of the strategy group) (2011) Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis. Nature 476: 214-219.
• Siffrin V, Radbruch H, Glumm R, Niesner R, Paterka M, Herz J, Leuenberger T, Lehmann SM, Luenstedt S, Rinnenthal JL, Laube G, Luche H, Lehnardt S, Fehling H, Griesbeck O, Zipp F (2010) In vivo imaging of partially reversible th17 cell-induced neuronal dysfunction in the course of encephalomyelitis. Immunity 33: 424.
• Schulze-Topphoff U, Prat A, Prozorovski T, Siffrin V, Paterka M, Herz J, Bendix I, Ifergan I, Schadock I, Mori MA, Van Horssen J, Schröter F, Han MH, Bader M, Steinman L, Aktas O§, Zipp F§ (2009) Activation of kinin receptor B1 limits encephalitogenic T lymphocyte recruitment to the central nervous system. Nat Med 15: 788. §equally contributing
• Siffrin V, Brandt AU, Radbruch H, Herz J, Boldakowa N, Leuenberger T, Werr J, Hahner A, Schulze-Topphoff U, Nitsch R, Zipp F (2009) Differential immune cell dynamics in the CNS cause CD4+ T cell compartmentalization. Brain 132: 1247-1258
• Prozorovski T, Schulze-Topphoff U, Glumm R, Baumgart J, Schröter F, Niemann O, Siegert E, Bendix I, Brüstle O, Nitsch R, Zipp F§, Aktas O§ (2008) Sirt1 critically contributes to the redox-dependent fate of neural progenitors. Nat Cell Biol 10: 385. §equally contributing
• Wuerfel J, Haertle M, Waiczies H, Tysiak E, Bechmann I, Wernecke KD, Zipp F§, Paul F§ (2008) Perivascular spaces - MRI marker of inflammatory activity in the brain? Brain 131: 2332-2340
• Paul F, Jarius S, Aktas O, Bluthner M, Bauer O, Appelhans H, Franciotta D, Bergamaschi R, Littleton E, Palace J, Seelig HP, Hohlfeld R, Vincent A, Zipp F (2007) Antibody to Aquaporin-4 in the Diagnosis of Neuromyelitis Optica. PLoS Med 4: 669-674
• Aktas O, Smorodchenko A, Brocke S, Infante-Duarte C, Schulze Topphoff U, Vogt J, Prozorovski T, Meier S, Osmanova V, Pohl E, Bechmann I, Nitsch R, Zipp F. (2005) Neuronal damage in autoimmune neuroinflammation mediated by the death ligand TRAIL. Neuron 46: 421-432.
• Würfel J, Bellmann-Strobl J, Brunecker P, Aktas O, McFarland H, Villringer A, Zipp F (2004) Changes in cerebral perfusion precede plaque formation in Multiple Sclerosis - A longitudinal Perfusion MRI study. Brain 127: 111-119
• Wandinger KP, Lunemann JD, Wengert O, Bellmann-Strobl J, Aktas O, Weber A, Grundstrom E, Ehrlich S, Wernecke KD, Volk HD, Zipp F (2003) TNF-related apoptosis inducing ligand (TRAIL) as a potential response marker for interferon-beta treatment in multiple sclerosis. Lancet 361: 2036-2043.
• Nitsch R, Bechmann I, Deisz RA, Haas D, Lehmann TN, Wendling U, Zipp F (2000) Human brain-cell death induced by tumour-necrosis-factor-related apoptosis-inducing ligand (TRAIL). Lancet 356: 827-828.
• Zipp F, Weil JG, Einhaupl KM (1999) No increase in demyelinating diseases after hepatitis B vaccination. Nat Med 5: 964-965.